RxDoctor Payments Data

Carl Frosina, MD

Internal Medicine · Pell City, ALNPI 1558346312

Payments from drug & device makers

$878in general payments, 2019–2025

Across 49 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$203
  • Indivior Inc.$146
  • MDD US Operations, LLC$112
  • Collegium Pharmaceutical, Inc.$111
  • Braeburn Inc.$102
  • AbbVie$59
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$50,095
Medicare patients
230
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine41$83,960
Buprenorphine339$79,472
Xtampza ErOxycodone Myristate104$56,599
BelbucaBuprenorphine Hcl68$48,493
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,295$28,846
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl137$23,249
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,076$20,431
ZtlidoLidocaine22$19,412
OxycontinOxycodone Hcl32$15,592
MovantikNaloxegol Oxalate30$12,070
Lidocaine111$10,811
LinzessLinaclotide20$10,495
SymproicNaldemedine Tosylate18$7,941
Diclofenac Sodium189$5,947
Gabapentin610$5,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$111$105,092172 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone$18$102,721476 claims
Indivior Inc.Sublocade$146$83,96041 claims
Scilex Pharmaceuticals Inc.Ztlido$34$19,41222 claims
AbbVieLinzess$59$10,49520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Pell City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →